However, researchers sometimes use BPC-157 alongside GLP-1 therapies to address gastrointestinal side effects, given its demonstrated gastroprotective properties
Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes management Dysgeusia (taste disturbance) is not listed in the UK Summary of Product Characteristics for Ozempic Potential contributing factors include gastrointestinal side effects, dehydration, concurrent medications, vitamin B12 deficiency, or oral health issues Management includes good oral hygiene, dietary modifications, staying hydrated, and reviewing concurrent medications with your healthcare provider Contact your GP if metallic taste persists beyond 23 weeks, affects nutritional intake, or accompanies other concerning symptoms Alternative diabetes medications include other GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors, or insulin therapy as recommended by NICE guidance Table of Contents What Causes Metallic Taste When Taking Ozempic
Your friendly guide to GLP-1 weight loss: What works, what doesnt, and whats next
Companies including Pfizer, Eli Lilly, and Structure Therapeutics are leading the charge in developing novel orals
Retrieved from Dorling, J., Broom, D
